Heather Wood,Nabila Hamdi
Heather Wood
Heather Wood
Heather Wood
Heather Wood
Heather Wood
ZFP384 targeting maintains microglial reparative activity after stroke [0.03%]
ZFP384靶向在卒中后维持小胶质细胞的修复作用
Heather Wood
Heather Wood
MRI end-points for clinical trials in ataxias: recommendations from the Ataxia Global Initiative MRI Biomarkers Working Group [0.03%]
小脑共济失调临床试验的磁共振终点指标：来自国际共济失调联盟MRI生物标志物工作组的建议
Gülin Öz,Sirio Cocozza,Thiago J R Rezende et al.
Gülin Öz et al.
Disease-modifying therapies for degenerative ataxias, including emerging gene therapies, are in the clinical trial pipeline. Sensitive outcome measures are urgently needed for treatment monitoring and participant selection to improve trial ...
Freja Sadler,Sarah J Tabrizi
Freja Sadler
Jeannine M Heckmann,Niki Floudiotis,Akintomiwa Makanjuola et al.
Jeannine M Heckmann et al.
Motor neuron disease (MND) refers to a group of neurodegenerative diseases that cause motor neuron degeneration and death. The most common subtype, amyotrophic lateral sclerosis (ALS), is characterized by both upper and lower motor neuron i...
Luca Prosperini,Carla Tortorella,Frederik Barkhof et al.
Luca Prosperini et al.
Multiple sclerosis (MS) is a condition marked by considerable prognostic uncertainty, despite advances in therapeutic strategies and biomarker development. Current approaches to prognosis are largely focused on disease burden, failing to co...
Paola Barbarino
Paola Barbarino
Didu S Kariyawasam,Giovanni Baranello,Michelle A Farrar
Didu S Kariyawasam